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1 Introduction 
 
1.1 ERp57 
 
The endoplasmic reticulum (ER) serves many general functions, 
including the facilitation of protein folding and the transport of newly 
synthesized protein. Moreover, ER has functions in several metabolic 
processes, such as lipids and steroids synthesis, in protein post-translational 
modifications, in the regulation of calcium concentration and in modulation 
of the stress responses. There are ER numerous proteins dealing with these 
different functions. One of these proteins, ERp57, is an ER luminal 
glycoprotein specific thiol oxidoreductase that is a member of the protein 
disulfide isomerase (PDI) family (Freedman et al. 1994). 
ERp57 has been referred to as Grp58, ERp60, ERp61, PDI-Q2, PDIA3 
and 1,25D3-MARRS (Membrane Associated, Rapid Response Steroid 
binding). 
ERp57 has been most widely studied for its role in the immune system 
because of its involvement in the heavy chain assembly of major 
histocompatability complex (MHC) class I molecules (Wearsch and 
Cresswell 2008). Nevertheless, there is an increasing number and type of 
functions in which it seems to be involved. 
In 1988 the cDNA encoding ERp57 (then referred to as ERp60) was first 
isolated from numerous animal species and mistakenly identified as 
phosphoinositide-specific phospholipase C (PI-PC) with surprising amino 
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acid sequence similarity of ERp60 thioredoxins (Bennett et al. 1988). A 
decade after this finding, the cDNA encoding human ERp57/Grp58 was 
cloned independently in three different laboratories (Bourdi et al. 1995; 
Hirano et al. 1995; Koivunen et al. 1997). All of them reported that the gene 
encodes a 505-amino acid polypeptide with significant homology to human 
protein disulfide isomerase. 
The sequence includes a putative nuclear localization motif and a 
endoplasmic reticulum retention/retrieval motif (Bourdi et al. 1995). 
The human gene encoding ERp57 consists of 13 exons and 12 introns, 
spans 18 kb in length and encodes a 505 amino acid protein, that is highly 
expressed in human liver, lung, placenta, pancreas and kidney; with lowest 
expression in the heart, skeletal muscle and brain (Koivunen et al. 1997). 
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1.1.1 Structure 
 
ERp57 has distinct structural and functional domains (Fig. 1). 
 
 
 
 
 
Figure 1.  A linear representation of ERp57 and B three-dimensional model of ERp57. 
The protein contains an N-terminal amino acid signal sequence and a C-terminal QDEL 
endoplasmic reticulum (ER) retention signal. In both the linear and three-dimensional model, 
the catalytic a and a‟ domains are shown in light grey while the substrate binding b and b‟ 
domains are shown in dark grey. The yellow amino acids indicate the catalytic residues 
CGHC and the blue amino acids indicate residues involved in calnexin binding. In the linear 
model, the short linker between the b and b‟ domains is marked in orange and the basic C 
terminal is marked in purple. Three-dimensional model of the a b b‟ a‟ domains based on 
NMR studies of the a and a‟ domain of protein disulfide isomerase (PDI) (Tian et al. 2006) 
and the b and b‟ domains of ERp57 (Kozlov et al. 2006).(Coe and Michalak 2010). 
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ERp57 has a domain architecture of four thioredoxin-like domains (a 
b b’ a’) and is highly similar to PDI in both domain organization and amino 
acid sequence and sharing with this protein the 33% overall identity (Kozlov 
et al. 2006). NMR studies have shown that ERp57 adopts an overall U shape 
similar to that of PDI with the catalytic sites of the two active thioredoxin 
domains facing each other. 
The ERp57 a and a’ domains are highly similar to PDI sharing 50% 
amino acid identity in these catalytically active CGHC motif domains. Both a 
and a’ domains show characteristic features of folded proteins, having both α 
strands and β sheets with no noticeable differences in the secondary structure 
when oxidized or reduced a‟ domain are compared. The a domain, containing 
a structural disulfide bond formed between two cysteines (Cys61 and Cys68), 
presents only minor differences in both redox state (Frickel et al. 2004). 
The redox potentials of the of ERp57 a and a’ domains are −0.167V 
and −0.156 V, respectively, and these potentials are comparable to the redox 
potential of PDI (−0.175 V). The disulfide reductase and isomerase activities 
of the a and a‟ domains are 20 times lower than those of PDI.  
The ERp57 b and b’ domains are two thioredoxin-like domains 
connected by a short linker. They are critical for binding to the lectin-like ER 
chaperone calnexin (Kozlov et al., 2006). 
The b and b’ domains have approximately 20% amino acid identity to 
PDI, but the ERp57 b‟ domain has a long deletion while the b domains of 
ERp57 has two 6–7 residue inserts; this loop contains residues that are 
critical for binding to calnexin (Kozlov et al., 2006). 
As mentioned before, ERp57 has a ER retrieval sequence (QEDL) in 
its C-terminal and unlike PDI, does not have an acidic carboxyl terminus but 
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instead a basic carboxyl terminal domain: this difference modulate the 
substrate binding specificity (Khanal and Nemere 2007).  
 
 
 
Figure 2.  Organization of the a b b’ a’ domains of ERp57 compared with PDI. 
The residue numbers of the individual thioredoxin-like domains are given. The a b b‟ a‟ 
domains of ERp57 and PDI are similar, except that ERp57 has a basic C-terminus and PDI 
has an acidic c domain.(Pollock et al. 2004) 
 
Interestingly, PDI and ERp57 also show a deep difference in their b 
and b’ domains surface charges. In fact, there is a formal charge of +4 in the 
b‟ ERp57 α2‟ helix, while in PDI this charge is −4. The positive charge of 
ERp57 has a role in binding the negative tip of the P-domain of calnexin. 
When these residues are mutated the binding to calnexin is abrogated. Hence, 
the b’ domain is critical for the binding of calnexin, while the b domain 
strengthens this interaction. 
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1.1.2 Main ERp57 biological functions 
 
ERp57 has been reported to be involved in a variety of cellular functions, 
summarized in Table 1( reviewed in Turano et al.2011). 
 
 
Table 1 Localizations, activities and functions of ERp57. (Turano et al. 2011) 
Locations Activity Function Ref. 
Endoplasmic 
reticulum 
Disulfide isomerase  Folding monoglucosylated 
proteins 
(Oliver et al. 1997; 
Oliver et al. 1999) 
Disulfide isomerise Dissociation of the capsid 
proteins of SV40 
(Schelhaas et al. 
2007) 
Disulfide bond formation  
 
Assembly of the major histo-
compatibility complex (MHC) 
class I 
(Lindquist et al. 
1998) 
Redox activity Redox state of the sulfhydryl 
groups in the intraluminal 
portion of SERCA 
(Li and Camacho 
2004) 
Interaction with the all-trans 
retinoic acid receptor α  
Submit the receptor to the 
degradation process known as 
ERAD 
(Zhu et al. 2010) 
Interaction with STAT3, in 
mouse embryonic fibroblasts 
Modulation of STAT3 
signaling from the lumen of the 
endoplasmic reticulum 
(Coe et al. 2010) 
Cell surface Interaction with calcitriol Fast activation of non-genomic 
processes of calcitriol 
(involving PLA2; PKC; ERK) 
Stimulation of phosphate 
uptake. 
Internalization and nuclear 
import 
 
(Nemere et al. 2004) 
(Boyan et al. 2007; 
Tunsophon and 
Nemere 2010) 
(Wu et al. 2010) 
  Regulation of bone-related 
gene transcription and 
mineralization in osteoblast-
like MC3T3-E1 cells 
(Chen et al. 2010) 
 Interaction with the  (Mah et al. 1992) 
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angiotensin II receptor 
 Interaction with vasopressin 
receptor 
 (Aiyar et al. 1989) 
 Interaction with the all-trans 
retinoic acid receptor α 
 (Zhu et al. 2010) 
 Interaction with STAT3 in the 
lipid raft fraction of cell 
membrane 
 
Participation of a signal 
transduction pathway 
initiating at the cell surface 
(Sehgal et al. 2002) 
(Guo et al. 2002) 
Cytosol 
 
Interaction with STAT3 in the 
cytosol 
Present in a multiprotein 
complex 
 
(Ndubuisi et al. 1999) 
(Guo et al. 2002) 
 Interaction with the all-trans 
retinoic acid receptor α 
Transport of the ligand-
receptor complex into the 
nucleus (in the Sertoli cells) 
(Zhu et al. 2010) 
 Interaction with NFκB in the 
cytosol of leukemic cells 
 (Wu et al. 2010) 
 Redox activity; interaction 
with Ref-1 
 
Maintenance of the reduced 
state of Ref-1 
(complex, shuttles between the 
cytosol and the nucleus) 
(Grillo et al. 2006) 
 Interaction with mTOR  Assembly and functioning of 
the multiprotein complex 
mTORC1; 
Appears to be at least in part 
responsible for the redox 
dependence of mTORC1 
activity 
(Ramirez-Rangel et 
al.) 
Nucleus Redox activity; interaction 
with Ref-1 
 
Maintenance of the reduced 
state of Ref-1 
(complex, shuttles between the 
cytosol and the nucleus) 
(Grillo et al. 2006) 
 Interaction with STAT3  
 
Binding to enhancers, known to 
bind STAT3 for the activation 
of the corresponding genes; 
involvement in the signaling 
and/or DNA binding of STAT3 
(Chichiarelli et al. 
2007) 
 
 Protein complex with 
HMGB1, 
HMGB2, HSC70, 
glyceraldehyde 
3-phosphate dehydrogenase 
and 
ERp57  
Recognition of the 
incorporation of the modified 
nucleosides into the DNA 
(resulting in genotoxic stress, 
eventually leading to 
apoptosis); ERp57 is essential 
for the phosphorylation of 
histone H2AX  
(Krynetski et al. 
2003) 
(Krynetskaia et al. 
2009) 
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 Interaction with Ku80, Ku70 
and nuclear matrix protein 
200/hPso4 
Participation in more than one 
process of DNA repair 
(unknown mechanism) 
(Grillo et al. 2006) 
 
 
Presence in multimeric nuclear 
complexes, containing 
nucleophosmin, nucleolin, 
TUBB3 (a specific isotype of 
tubulin) and β-actin 
The interaction appeared to be 
correlated with paclitaxel 
resistance 
(Chichiarelli et al. 
2007) 
(Schultz-Norton et al. 
2006) 
 Interaction with A/T rich 
regions, 
and in general with MARs 
(nuclear matrix associated 
regions) of DNA; Binding 
requires the oxidized form of 
ERp57 
 (Grillo et al. 2007) 
(Coppari et al. 2002) 
 
 
Redox activity on transcription 
factor E2A (stabilized by 
disulfide bonds) 
Responsible for the inactivation 
of the factor by reducing its 
disulfide bonds 
(Markus and Benezra 
1999) 
Mitochondria Interaction with calpain Stabilize calpain, contrasting 
with its degradation by other 
mitochondrial proteases; 
ERp57-calpain complex- 
catalyzed partial hydrolysis of 
AIF 
(Ozaki et al. 2008) 
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1.1.3 ERp57 as a member of the chaperone system 
 
The first well characterized function of this thiol-disulfide 
oxidoreductase in the ER is the one typical of the chaperone proteins. 
For recently synthesized glycoproteins, the ER possesses a specific 
maturation system designed to assist in folding, thereby ensuring the quality 
of the final products before they are released. 
Proteins that are not properly folded are sent to proteosomes for 
degradation. The molecular components of this folding system are usually 
referred to as “chaperones”. 
Being a member of the thiol oxidoreductase family of proteins that 
facilitate the oxidative folding of glycoproteins (Urade et al. 2004), it 
catalyzes disulphide bond exchange in substrates that are bound to 
calreticulin (CRT) or calnexin (CXN) (Martin et al. 2006). 
ERp57 interacts specifically with N-glucosylated integral membrane 
proteins and substrate selection is dependent upon its formation of discrete 
complexes with soluble CRT or membrane bound CXN (Zapun et al. 1998). 
It has been suggested that calnexin or calreticulin has a role in 
bringing ERp57 and substrate into close proximity, increasing their local 
concentration, resulting in an apparent enhanced activity of ERp57 (Leach et 
al. 2002). 
The process requires the intermediate formation of a mixed disulfide 
between the glycoprotein and the proximal cysteine of one of the two active 
sites of ERp57in oxidation, reduction and isomerisation reactions (Leach et 
al. 2002). 
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1.1.4 ERp57 in immune function: MHC class I molecules 
 
One of the most widely studied function of ERp57 is its role in the 
immune system. 
The function of the major histocompatibility complex (MHC) class I 
molecules is to present cytoplasmatically derived short peptides to cytotoxic 
T lymphocytes, which can potentially trigger a cascade of immune responses 
(Pamer and Cresswell 1998). Extracellular pathogens are initially 
endocytosed and degraded by the proteasome. These peptides are then 
traslocated in to the ER lumen through a well described pathway, the TAP 
system. Once within the ER, they are presented to the nascent MHC class I 
and if the pocket on this protein is complementary, it binds it. The complex is 
then translocated to the plasma membrane where it presents the bound 
peptide to the various immunoreactive cells. 
In studying MHC class I production, interactions with chaperones 
were identified. The first of these proteins to be identified in association with 
the MHC class I heavy chain was calnexin (CXN) (Degen and Williams 
1991), which ERp57 requires for its recruitment to heavy chain in the ER. In 
the early stage, the glycosylated heavy chain binds to both calnexin and 
ERp57, and this complex catalyzes disulfide bond formation in the heavy 
chain, allowing it to assemble with the soluble subunit β2-microglobulin. At 
the late stage, these heterodimers acquire peptides, thus entering the peptide 
loading complex (PLC) which consists of calreticulin; ERp57; a peptide 
transporter (TAP) and tapasin, a glycoprotein critical for loading MHC class I 
molecules with high affinity peptides. Peptides are then loaded in the ER and 
the heavy chain β2-microglobulin heterodimer dissociates from the PLC and 
is exported to the cell surface (Zhang et al. 2009).  
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Figure 3.  Within the ER, newly synthesized H chains (green) associate with the membrane-
bound molecular chaperone calnexin (orange) and ERp57 (purple). The calnexin-H chain 
complex then binds to the β-2m subunit (green). At this point, calnexin may remain or it may 
be replaced by its soluble homolog calreticulin . Yet another protein, Bap31 (blue), binds at 
this stage. Subsequent association with the TAP transporter (orange) occurs in an interaction 
that is bridged by tapasin (pink). This multi-subunit complex consisting of calnexin (or 
calreticulin), H chain, β-2m, tapasin, TAP, ERp57 and Bap31 is known as the "peptide-
loading complex" or PLC. Following peptide binding to class I, the peptide loading complex 
dissociates and the fully assembled class I molecule is exported to the cell surface. Once at 
the cell surface, peptide-class I complexes are scrutinized by T cell receptors on circulating 
cytotoxic T cells. If the T cell receptor binds with sufficiently high affinity, the infected cell 
will be killed. 
 
The centrality of ERp57 in antigen processing is underscored by the 
impaired assembly of the MHC class I peptide-loading complex in mice 
deficient in it and the embryonic death of all 64 mouse embryos thath were 
exposed to ubiquitous deletion of the protein (Garbi et al. 2006). 
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1.1.5 ERp57 as membrane associated receptor 
 
An unexpected function of ERp57 on the cell surface is the binding of 
the hydroxylated, hormonal form of vitamin D3, i.e. 1α,25-
dihydroxycholecalciferol (1α,25-(OH)2D3, calcitriol) (Nemere et al. 2004), 
followed by fast activation of non-genomic processes and the internalization 
and nuclear import of ERp57 itself. This finding was the consequence of a 
search for a membrane receptor, whose existence was established by ligand 
binding studies. Rapid responses are not expected to be the result of the 
involvement of the classical vitamin D receptor (VDR), which operates 
through binding to DNA and the activation of gene expression, and therefore 
requires longer times to produce detectable events. The rapid cell response 
(seconds or minutes) after stimulation with 1α,25-(OH)2D3 activates 
numerous cascades of signal transduction, involving signaling proteins such 
as phospholipases C (PLC) and A2 (PLA2), protein kinases C (PKC) and 
ERK (extracellular response activated kinase), all of which have been shown 
to respond to the formation of the ERp57-1α,25-(OH)2D3 complex (Chen et 
al. 2010). 
ERp57 is also important for the steroid hormone-stimulated calcium 
uptake in mammalian intestinal cells (Nemere et al. 2010). ERp57 modulates 
the vitamin D-mediated anti-cancer activity, specifically in breast cancer. 
1,25(OH)2D3 stimulates PLA2-dependent rapid release of 
prostaglandin E2 (PGE2), activation of protein kinase C (PKC), and 
regulation of bone-related gene transcription and mineralization in osteoblast-
like MC3T3-E1 cells via a mechanism involving ERp57 (Chen et al. 2010). 
These data suggest that ERp57 is an important initiator of 1,25(OH)2D3-
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stimulated membrane signaling pathways, which have both genomic and non-
genomic effects during osteoblast maturation (Chen et al. 2010). 
 
 
1.1.6 ERp57 as a stress-response protein 
 
ERp57 has been initially identified as a protein overexpressed in K12 
cells, subjected to a stress caused by glucose depletion. This overexpression 
response has subsequently been confirmed in many cell types and with 
different stress inducing agents (Murray et al. 2004). 
The chaperone and redox activities of overexpressed ERp57 are 
expected to counteract some deleterious effects of cell stress, such as  protein 
misfolding or damage caused by reactive oxygen species, and a number of 
studies have confirmed this behavior, although they have also revealed great 
differences in the response and in the protection provided, depending on the 
type of stress and on the cells which were examined. 
In some cases the knowledge of these effects might even be exploited 
for a therapeutic intervention, as proposed in a recent study (Corazzari et al. 
2007), in which the mechanism of action of antitumoral agents was 
investigated. 
A further example of cell-protecting activity of ERp57 emerged from 
the study of the neurodegenerative disease. 
Neurodegenerative disorders such as Alzheimer‟s disease (AD), 
Parkinson‟s disease (PD), Huntington‟s disease (HD), amyotrophic lateral 
sclerosis (ALS) and prion protein diseases all share a common feature: the 
accumulation and aggregation of misfolded proteins (Rao and Bredesen 
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2004). The presence of misfolded proteins elicits cellular responses that 
include an endoplasmic reticulum (ER) stress response that may protect cells 
against the toxic buildup of misfolded proteins. 
Accumulation of these proteins in excessive amounts, however, 
overwhelms the „cellular quality control‟ system and impairs the protective 
mechanisms designed to promote correct folding and degrade faulty proteins, 
ultimately leading to organelle dysfunction and cell death. The accumulation 
of misfolded proteins seen in various neurodegenerative diseases leads to an 
ER stress response. 
In light of this considerations, is not surprising the involvement of the 
protein ERp57 in numerous human disease states such as cancer, prion 
disorders, Alzheimer‟s and Parkinson‟s diseases and ALS (Erickson et al. 
2005; Hetz et al. 2005; Tourkova et al. 2005; Nardo et al. 2011; Wilhelmus et 
al. 2011). 
Expression of ERp57 is increased in transformed cells, and it is also 
thought that the role it plays in oncogenic transformation is directly due to its 
ability to control intracellular and extracellular redox activities through its 
thiol-dependent reductase activity (Hirano et al. 1995). Additionally, the role 
ERp57 in the modulation of STAT3 signalling and proliferation could be 
exploited and contribute to a cancerous diseased state (Coe et al. 2009). 
An increase in ERp57 expression has also been observed in the early 
stages of prion disease, suggesting that it may play a neuroprotective role in 
the cellular response to prion infection (Hetz et al. 2005). ERp57 and prion 
protein interact and this interaction is enhanced in prion infected mouse 
scrapies. 
Erickson et al. (2005) demonstrated that in Alzheimer‟s disease, 
ERp57 and calreticulin are carrier proteins that prevent the aggregation of β-
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amyloids, a major component of the toxic plaques found in Alzheimer 
patients. 
In PD brain, the tissue transglutaminase enzyme, that catalyzes 
molecular protein cross-linking and is present in a granular distribution 
patter, induces cross-links in α-synuclein monomers, oligomers and α-
synuclein aggregates. Apart from tTG, these granules were also positive for 
the protein disulphide isomerase, ERp57 and calreticulin (Wilhelmus et al. 
2011). 
Furthermore, impaired function because of oxidative/nitrosative 
modifications of PDI or increased expression of ERp57 in neuronal cells 
cultured in the presence of the dopaminergic neurotoxin 6-hydroxydopamine 
has been described (Holtz and O'Malley 2003; Kim-Han and O'Malley 2007). 
In summary, these studies implicate ERp57 as a marker of various 
disease states and demonstrate the importance of ERp57 as a target for 
developing novel strategies for treatment and early diagnosis of diseases. 
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1.1.7 Nuclear ERp57 and DNA binding 
 
As aforementioned, ERp57 is localized predominantly in the ER, but 
also present in cell surface and in cytoplasm. An interesting and least known 
feature of Erp57 is its localization and its role in the nucleus(Chichiarelli et 
al. 2007). Indeed, ERp57 has a putative nuclear localization signal in its C-
terminus that allows the translocation of the protein disulfide isomerase to the 
nucleus. ERp57 is associated with scaffold/matrix associated region 
(S/MAR)-like sequences of DNA (Coppari et al. 2002), and in melanoma 
M14 cells, ERp57 associated with signal transducer and activator of 
transcription 3 (STAT3) in the nucleus (Eufemi et al. 2004). Several studies 
have also shown that ERp57 sequesters both inactive and active STAT3, and 
may play a role in the regulation of STAT3 signaling (Coppari et al. 2002; 
Eufemi et al. 2004). 
ERp57 has unidentified functions in the nucleus, likely having 
pleiotropic effects on gene expression. By extension, dysregulation of ERp57 
signaling in the nucleus may contribute to hepatocellular carcinoma (HCC) 
(Grindel et al. 2011). 
ERp57 has a Rel homology binding domain (Khanal and Nemere 
2007), therefore, NF-kB could provide a carrier shuttle for ERp57 nuclear 
translocation. It was shown recently that ERp57 can associate with the 
transcription factor nuclear factor kB (NF-kB) in NB4 promyelocytic 
leukemia cells (Wu et al. 2010).
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2 Preamble 
 
This work intends to investigate the role of the ERp57 protein in two 
different contexts: i) as protein involved in gene expression regulation, ii) as 
stress response protein. 
In the nucleus, ERp57 is able to bind in vivo specific DNA intronic 
sequences having the features of regulatory regions. Based on this evidence, 
experiments have been devoted to demonstrate its involvement in the control 
of gene expression. 
The redox changes in the ER are integral parts of the 
neurodegenerative patho-mechanisms, either as causative agents, or as 
complications. Recent findings strongly support a role of ERp57 protein in 
different neurodegenerative diseases such as Alzheimer and Parkinson‟s 
diseases. Kim-Han et al. (2007) point out that a mimetic parkinsonian 
neurotoxin 6-OH-dopamine leads to the rapid formation of high-molecular-
weight species of ERp57 and mitochondrial DNA in a dose and time-
dependent fashion. Therefore, the stress condition induced by a new 
endogenous neurotoxin 5-S-Cysteinyldopamine (CysDA), has been 
evidenced by oxidative stress markers such as protein carbonylation and 
glutathione levels. Considering the oxidative stress exerted by CysDA, its 
effects on the distribution and expression of a stress response protein as 
ERp57 was evaluated. 
18  
 
 
 
 
Aim of the work I 19 
 
 
 
 
3 Aim of the work I 
 
The idea of a nuclear localization of ERp57 was at first not easily 
accepted, not only because the escape of a protein, provided with an ER 
retention signal, from the endoplasmic reticulum was considered unlikely, 
but also because of the endoplasmic reticulum shares its membrane with the 
nucleus. 
The first evidence of the nuclear presence of ERp57 emerged from 
immunofluorescence detection in 3T3 cells and rat spermatids (Ohtani et al. 
1993) and from a proteomic study of chicken hepatocytes nuclei, where 
ERp57 was mainly found localized in the internal nuclear matrix fraction 
(Altieri et al. 1993).  
Subsequently, the presence of ERp57 was demonstrated in the internal 
nuclear matrix obtained from 3T3 and HeLa cells. Futher evidences 
indicating Erp57 nuclear localization was obtained from data showing the 
protein associated to DNA cross-linked with cis-diamminedichloroplatinum 
II (cis-DDP) or formaldehyde (Coppari et al. 2002). 
Moreover, Markus and Benezra have highlighted a regulatory activity 
of ERp57 on the redox state and functional properties of the E2A 
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transcription factor, hypothesizing a role for ERp57, as modulator of 
trascription factors (Markus and Benezra 1999). 
The findings by Krynetski and coworkers (Krynetski et al. 2003) 
demonstrated that ERp57 was present in a multiprotein complex responsible 
for recognition of DNA damage in cells with an inactive mismatch repair 
system. This hypothesis has been further corroborated by the association with 
the human apurinic/apyrimidinic endonuclease (APE/Ref-1) (Grillo et al. 
2006), a dual-function protein that has important roles in the repair of 
baseless sites that arise in DNA and in regulating the redox state of several 
proteins (Yacoub et al. 1997). 
Previous data obtained in our lab, have demonstrated that ERp57 was 
able to interact with MSH6, TMEM126A and Ets-1 gene sequences in HeLa 
cells (Chichiarelli et al. 2007) and in melanoma cell line (M14) cells by ChIP 
assay (Aureli et al., 2011 submitted). In particular, MSH6 (muts homolog6 
(E. coli) gene sequence is the fourth intron of the gene located on 
chromosome 2; it is involved together with MSH2, in the repair of base 
substitutions and small mismatched loops (Martin et al. 2010). The second 
gene sequence of interest, TMEM126A is a portion of the 5' region of the 
gene TMEM126A, strongly expressed in the brain, which encodes for 
mitochondria-localized mRNA (MLR) proteins and may be essential in the 
early nucleation process of large mitochondrial complexes (Hanein et al. 
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2009). Ets-1 (E26 transformation-specific sequence) gene sequence is an 
intron of Ets-1 gene and it is a member of the Ets family transcription factors 
that play many roles in different biological processes such as cell growth and 
survival (Hanein et al. 2009). Moreover, it has been demonstrated that Ets-1 
is implicated in melanoma cells protection under ER stress-induced apoptosis 
(Dong et al. 2011). 
The following actions were taken to get more insight into the role of 
ERp57 in gene expression regulation: 
 MSH6, TMEM126A and Ets-1 chromatin regions were analyzed 
for their sensitivity to DNase I digestion.  
 The influence of ERp57 on MSH6, TMEM126A and Ets-1 gene 
expression was evaluate by RNA interference strategy and 
subsequent Real-Time PCR analyses  
 To assess the interaction of MSH6, TMEM126A and Ets-1 with 
ERp57 and its potentially related proteins in vitro binding assay 
were performed.
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4 Materials and Methods I 
 
4.1 Cell Culture 
 
Human melanoma (M14) cells were grown to 70-80% confluence at 37°C 
and in an atmosphere of 5% CO2 in RPMI 1640 medium, supplemented with 
10% fetal bovine serum, 1% w/v sodium pyruvate, 2mM glutamine, 100 
U/ml of penicillin and 100 µg/ml of streptomycin. 
 
 
4.2 Detection of DNase I hypersensitivity 
 
Nuclei from M14 cells were purified as previously described by 
Chichiarelli et al., 2007. Briefly, M14 cells were manually scraped and 
washed three times with PBS by centrifuging 5 min at 1,500g. Cells were 
lysed in lysis buffer (50 mM Tris-HCl pH 7.9, 100 mM KCl, 5 mM MgCl2, 
0.025% Triton X-100, 50% 1 g Glycerol, 200 mM β-mercaptoethanol, 0.15 
mM spermine, 0.5 mM spermidine), supplemented with the inhibitor 
cocktail, by incubation on ice for 15 min, and were then centrifuged for 15 
min at 1,300g. The pellet was resuspended in Buffer A (50 mM Tris-HCl pH 
7.9, 100 mM NaCl, 3 mM MgCl2, 1 mM DTT, 0.2 mM PMSF, 0.15 mM 
spermine, 0.5 mM spermidine) and centrifuged 15 min at 1,300g. The 
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purified nuclei were stored at -80°C in Buffer A (0.25 mg DNA/ml). The 
whole procedure was performed at 4°C. 
The DNase I hypersensitivity assay was performed as described by 
Sambrook and Russel (2001) by treating the nuclei at 37°C for 20 min with 
different amounts of DNase I; 0.0625U/l (1/160) and 0.015625U/l (1/640), 
respectively. The DNA hypersensitive regions were identified according to 
Feng and Villeponteau (1992) by means of a semi-quantitative PCR analysis. 
The PCR amplification of the different clones was performed amplifying 
each clone PCR with JumpstartREDAccuTaq (Sigma) and a Perkin Elmer 
thermal Cycler 2400, using the program steps showed in Table2. The 
obtained PCR samples were subjected to 2% agarose gel electrophoresis. 
 
Table 2. Program steps for PCR amplification of the different clones 
Denaturation 96°C 60 sec 
Cycle 1-25:   
Denaturation 94°C 15 sec 
Annealing 57°C 30 sec 
Extension 68°C 2 min 
Final extension 68°C 10 min 
 
 
The method was tested on two well-characterized sequences present in 
the 5‟-region of the MYC gene (Mautner et al., 1995). One, here indicated as 
Myc-2, is known to be DNase hypersensitive (NC_000008, from 128820577 
to 128821252), the other, here indicated as Myc-3, is known to be DNase 
resistant (NC_000008, from 128811402 to 128811787). The best 
reproducible results were obtained when the DNA remaining intact after a 
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digestion with 5 U/ml of DNase I was compared to that remaining intact with 
1.25 U/ml of DNase I. In the latter condition the initial fragmentation of 
DNA favored a complete recovery of the DNA subjected to purification and 
amplification. 
The analysis of DNase I hypersensitivity was carried out in more detail 
using three couples of primers: MSH6, TMEM126A and Ets-1 (Table 3). 
 
Table 3. couples of primers for PCR amplification 
 Left Primer  Right Primer 
Myc2 5‟-TCATACACCTCTGAAACCTTGG-3‟ 5‟-TAATGAGGCTTTGGACACACC-3‟ 
Myc3 5‟-ATAGCAGAGACAGGCCAGTGA-3‟ 5‟-TTCCCCTCCTGGCTTTTAGTA-3‟ 
MSH6 5‟-GTTGCCCAGGCTAGAATATG-3‟ 5‟-AGAGGCTGACACGAGAGGTC-3‟ 
TMEM126A  5‟-AGAGGAGAGCATAAGGTACTGGT-3‟ 5‟-CTTGGAAGAGCTCTGAGAGATAGG-3‟ 
Ets-1 5‟-TGGATACTGCTAGGGCCAAC-3‟ 5‟-GGATAGGGGAGGAGTCAAGG-3‟ 
 
 
4.3 ERp57 siRNA silencing 
 
The silencing of the protein ERp57 in M14 cells was obtained by the 
administration of specific siRNA (Hs_GRP58_6_HP Validated siRNA, 
QIAGEN). The day before transfection, 2.5 x 104 cells per well of a 96-well 
plate in 100 µl of a complete culture medium (containing serum and 
antibiotics) were seeded. The cell cultures were grown under normal growth 
conditions. The siRNA was used at 0.3 µg/µl final concentration and 
LipofectamineTM RNAiMAX (Invitrogen) was used as transfection agent. 
The transfection was carried out according to the manufacturer‟s 
instructions. M14 cells were incubated with the transfection complexes under 
their normal growth conditions and gene expression was monitored at the 
mRNA or protein level after 48 hours. In the gene expression experiments, 
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cells treated with scrambled, non-specific siRNA duplex (AllStars Negative 
control siRNA from QIAGEN) were used as control reference to exclude any 
nonspecific effect due to the treatment. 
 
 
4.3.1 Total RNA extraction and cDNA synthesis 
 
Cells were harvested and total RNA was isolated with TRIzol Reagent 
(Invitrogen) following the manufacturer‟s instructions. RNA was precipitated 
by adding isopropanol, washed with 75% ethanol and dried air. The total 
RNA was resuspended in sterile RNase-free water and subjected to reverse 
transcription. 
The reverse transcription of total RNA was conducted with SideStep™ II 
QPCR cDNA Synthesis Kit (Stratagene), according to the manufacturer‟s 
instructions. The reaction was performed with a Perkin Elmer thermal Cycler 
2400. 
 
 
4.3.2 Real-Time PCR 
 
ERp57, MSH6, TMEM126A, Est1 cDNA expression was evaluated with 
specific primers (QuantiTect® QIAGEN) by Real-Time PCR (RT-PCR), 
which was performed using a MJ MiniOpticon Detection System (BioRad 
Laboratories, Ltd) by means of Brilliant® SYBR® Green QPCR Master Mix 
(Stratagene) and according the following steps: denaturation (95°C for 5 
min), amplification repeated 40 times (95°C for 30 s, 55°C for 30 s, 72°C for 
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30 s). A melting curve analysis was performed following every run to ensure 
a single amplified product for every reaction. PCR fluorophore acquisition 
temperatures were set from 40°C to 95°C, reading every 0.5°C. 
All reactions were carried out in at least duplicate. GAPDH (RT2-PCR 
primers from SuperArray) and RPS27A (QuantiTect® QIAGEN) genes were 
used as reference for normalization and the relative quantification was 
analysed using Gene Expression Analysis for iCycler iQ Real Time PCR 
Detection System Software, Version 1.10 (BioRad Laboratories, Ltd). 
 
 
4.4 In vitro Binding Assay 
4.4.1 Nuclei purification and nuclear extracts preparation 
 
Cultured cells were scraped, harvested by centrifugation at 440g for 5 
min and washed twice with PBS.  
Cells were resuspended in a hypotonic lysis buffer [10 mM Hepes, pH 8, 
10 mM KCl, 1.5 mM MgCl2, 30 mM sucrose, 0.5 mM dithiothreitol (DTT), 
supplemented with an inhibitor cocktail (1 mM phenylmethylsulfonyl 
fluoride, 10 µM amido-phenylmethyl sulfonyl fluoride; 0.2 mM L-1-chloro-
3-(4-tosylamido)-4-phenyl-2-butanone, 0.15 µM aprotinin, 1 µg/ml E 64, 1 
µM pepstatin)] by using an hypodermic needle. The suspension was 
incubated in ice for 10 min and was then centrifuged at 1,400g for 10 min at 
4°C. The pellet, that contains the nuclei, was resuspended in lysis buffer and 
0.05% Triton X-100 and after incubated in ice for 10 min. The suspension 
was centrifuged at 1,400g for 10 min and the pellet was washed three times 
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with lysis buffer with 1 mM CaCl2, by centrifuging each time at 1,400g for 
10 min at 4°C.  
Nuclear extracts were obtained by treating the purified nuclei in ice for 30 
min with EN buffer (20 mM Hepes, pH 7.9; 10 mM KCl; 0.42M NaCl; 20% 
glycerol and the inhibitor cocktail). After the incubation with EN buffer the 
suspension was centrifuged at 10,000g for 20 min at 4°C. The supernatant 
contains the nuclear extract, while the pellet was resuspended again in EN 
Buffer and was incubated in ice for 30 min. The suspension was centrifuged 
at 10,000g for 20 min at 4°C and the supernatant, containing the nuclear 
extract was added to the first supernatant rate. 
 
 
4.4.2 Amplification of the biotinylated DNA fragments 
 
A biotinylated DNA fragments, corresponding to the genes MSH6, 
TMEM126A, and Ets-1, were obtained by PCR using the same primers 
described in table 3. 
The amplification of the biotinylated DNA sequence was performed 
using total DNA from M14 cells (40ng/μl stock solution) and 
JumpstartREDAccuTaq (Sigma). A Perkin Elmer thermal Cycler 2400 was 
utilized for the PCR amplification and the protocol used was the following: 
denaturation (96°C for 1 min), amplification repeated 30 times (94 °C for 
15s, 57 °C for 1min, 68 °C for 2mins) and extension (68 °C for 10mins). 
The amplification generated a single band displaying the predicted size. 
The amplified DNA fragments were then purified using a commercial kit 
(QIAEX® II Gel extraction kit, Qiagen). 
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4.4.3 Purification of multiprotein complexes by using Dynabeads 
 
Streptavidin-coated magnetic beads (Dynal) were washed three times in 
buffer A (10 mM Tris–HCl, pH 7.5; 1 mM EDTA, and 2M NaCl, protease 
inhibitor cocktail) using a magnetic separator (Dynal MPC). The biotinylated 
DNA fragments, corresponding to the genes MSH6, TMEM126A and Ets-1, 
were incubated with the beads (50 pmol of DNA for 0.5 mg of beads) for 2 
hours at 4 °C in buffer A (Sample). Control experiments were carried out by 
using streptavidin-beads saturated with biotin in buffer A (Control). 
Beads from Sample and Control were then incubated with 10nM biotin in 
buffer A for 15 min at 4 °C. The beads were isolated using the magnetic 
separator (Dynal MPC) and washed three times in buffer A. Subsequently the 
Beads from Sample and Control were incubated with 0.5% BSA in buffer A 
for 15 min at 4 °C and then were washed three times in buffer A and one time 
in buffer B (20 mM Tris-HCl pH 8, 5 mM EDTA, 5% glycerol, 0.1% 
Nonidet P40, protease inhibitor cocktail) using each time the Dynal MPC. 
The use of the 10nM biotin and of the 0.5% BSA is necessary to block the 
free streptavidin sites on the magnetic beads. 
The nuclear extracts was divided into two equal aliquots and one of these 
was mixed with DNA-coated beads (Sample), while the other one was mixed 
with biotin-coated beads (Control). The beads from Sample and Control were 
then incubated o.n. with gentle agitation at 4°C . The day after the beads were 
isolated using the Dynal MPC and washed four times in buffer C (20 mM 
Tris–HCl, pH 8; 5 mM EDTA; 5% glycerol; 0.1% Nonidet P40; 50mM NaCl 
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and the protease inhibitor cocktail), and once with buffer TE (10 mM Tris–
HCl, pH 8 and 1mM EDTA). 
The specifically bound proteins were eluted twice with 0,4M NaCl and 
subsequently twice with SDS buffer (62,5 mM Tris–HCl, pH 6.8; 2% SDS; 
10% glycerol; bromophenol blue). In each elution steps the beads were 
incubated with the elution buffers for 30 min with gentle agitation at room 
temperature. 
The eluted proteins from Sample and Control were analyzed by SDS-
PAGE and Western blotting using polyclonal anti-ERp57, anti-Ref1; anti-
Parp1 and anti-Ku86 antibodies. 
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5 Results I 
 
5.1 MSH6 and TMEM126A display DNase I hypersensitive sites 
 
Previous results obtained by Chichiarelli et al (2007) showed the 
interaction of ERp57 with MSH6, TMEM126A and Ets-1 gene sequences in 
HeLa and M14 cells. Therefore, DNase I hypersensitivity analyses were 
carried out to assess whether regulatory regions were localized in these gene 
sequences. 
To this purpose M14 cells nuclei were treated by decreasing 
concentrations of the enzyme DNase I and the DNA was then extracted and 
subjected to PCR using specific primers for the three regions of interest. A 
control sample was subjected to the same procedure without DNase I 
enzyme. 
The validity of the method was initially tested on two sequences located 
upstream with respect to the promoter of the proto-oncogene c-myc, human 
gene that regulates the processes of cell differentiation and proliferation. In 
particular Myc-2 and Myc-3 sequences were considered, since they are 
respectively hypersensitive and resistant to the action of the enzyme. 
As shown in Figure 4, DNase I-hypersensitive sites are present in Myc-2, 
as expected. Conversely, an increase of amplified Myc-3 DNA was detected 
at enzyme decreasing concentrations, indicating the presence of sites less 
sensitive to digestion. 
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Figure 4:  Myc-2 and Myc-3 sequences digested by DNase I. Samples treated with 
decreasing concentrations of DNase I, 0.0625U/l (S1) and 0.015625U/l (S2), respectively 
or untreated (C37) were analyzed by PCR and subjected to 2% agarose gel electrophoresis.  
 
 
Once the validity of the method was established, the same procedure was 
followed to analyze MSH6, TMEM126A and Ets-1 DNA sequences (Fig.5).  
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Figure 5:  MSH6, TMEM126A and Ets-1.sequences digested by DNase I. Samples 
treated with decreasing concentrations of DNase I, 0.0625U/l (S1) and 0.015625U/l (S2), 
respectively or untreated (C37) were analyzed by PCR and subjected to 2% agarose gel 
electrophoresis. 
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As reported in Figure 6 the densitometric analyses indicate that after 
DNase I digestion, MSH6 residual DNA was about 30% and 57% at 
0,0625U/l and 0.015625U/l enzyme concentration, respectively. 
TMEM126A, was about 19% and 20% at 0,0625U/l and 0.015625U/l 
enzyme concentration, respectively. Conversely, Ets-1 seems unresponsive to 
the DNase I action, as demonstrated by its 97% and 75% residual DNA 
obtained at higher and lower enzyme concentration, respectively. The values 
were normalized to the control sample (C37) and gene sequences are 
considered hypersensitive when DNA degradation is below 35% compared to 
the control as indicated by the black line on the graph. Therefore, MSH6 and 
TMEM126A seem to possess hypersensitivity site. 
 
Figure 6.  Densitometric analysis of MSH6, TMEM126A and Ets-1 digested by DNase I. 
M14 cells nuclei were treated  or untreated (C37) with decreasing concentrations of the 
enzyme DNase I, 0.015625U/l (1/640) and 0.0625U/l (1/160), respectively. DNA was 
then extracted and subjected to PCR using specific primers for the regions of Myc-2 and 
Myc-3. represent positive and negative control of DNase I digestion. The values were 
normalized against  the sample C37 used as control. 
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5.2 ERp57 siRNA silencing determines a decrease in the MSH6 
and TMEM126A genes expression 
 
To verify whether ERp57 is able to modulate MSH6, TMEM126A and 
Ets-1 genes expression, RNA interfering experiments were carried out using 
ERp57 short interfering RNA (siRNA).  
M14 cells were incubated with specific ERp57 siRNA for 48 hours 
under normal growth conditions. The silencing of the ERp57 gene and the 
trascribing activity of its target genes, MSH6, TMEM126A and Ets-1 mRNA 
were monitored by Real Time-PCR analyses. ERp57 protein silencing was 
achieved at 48 hours of treatment as demonstrated by Western blotting 
analysis of  M14 cell lysates (data not shown).  
The results showed that after 48 hours ,ERp57 mRNA expression was 
markedly reduced. Due to ERp57 silencing a significant MSH6 and 
TMEM126A genes expression down-regulation was obtained, whereas the 
Ets-1 gene was up-regulated, but this effect is not significant due to high 
standard deviation value gained by the ANOVA test (Fig. 7). 
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Figure 7.  Effect of silencing of ERp57 on the expression of three target genes (MSH6, 
TMEM126A and Ets-1). M14 cells were treated with the scrambled RNA (Scr) or siRNA 
for ERp57 (siRNA) and after 48h the total RNA was extracted and determinated by 
RealTime-PCR. RPS27A (QuantiTect
®
 QIAGEN) gene was used as reference for 
normalization and fold inductions were calculated using the formula 2
−(ΔΔCt)
. The relative 
quantification was analyzed using Gene Expression analysis for iCycler iQ real-time PCR 
detection system software, Version 1.10 (Bio-Rad Laboratories, Ltd.). The values represent 
the mean ± SD of at least three independent experiments. * p < 0.05 vs scrambled cells (Scr). 
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5.3 In vitro binding assay reveals the association of APE/Ref-1 
with the ERp57-interacting DNA fragments 
 
To evaluate whether ERp57, Ape/Ref-1(Ref1) and Ku86, both proteins 
involved in the ERp57 complex formation, or poly(ADP-ribose) polymerase-
1 (PARP-1), a protein implicated  in chromatin remodeling, were able to bind 
MSH6, TMEM126A or Ets-1 sequences in M14 cells, DNA binding assay 
was performed. MSH6, TMEM126A or Ets-1 sequences were biotinylated 
and immobilized on streptavidin-coated magnetic beads and then incubated 
with M14 nuclear extracts. The experiments were conducted in the presence 
of an excess of E. coli DNA used as a competitor. Proteins retained by the 
biotinylated DNA were eluted using a high salt concentration (0.4M NaCl), 
and then 2% SDS. The samples were subjected to Western blot analyses with 
Ref1, Ku86 and PARP1 antibodies.  
Figure 8.  Western blotting analysis with the ERp57, Ref-1, Ku86 and PARP1 
antibodies. The samples obtained by the elution of  immobilized cloned DNA sequences 
uncubated with M14 nuclear extract, were probed with the respective antibodies.(C) proteins 
fron nuclear extract boud to the beads without immobilized DNA regions (NE):represent the 
15% of  the total nuclear extract. The proteins were eluted with 0.4 M NaCl and then with 
2% SDS. 
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As shown in Fig. 8, Ref1 was associated with the regions of the MSH6, 
TMEM126A and Ets-1 genes, whereas Ku86 and PARP-1 bound to the genes 
in unspecific way . 
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6 Discussion I 
 
 
Previous results showed that ERp57 binds in vivo specific DNA targets, 
which are mainly present in intronic sequences having the features of 
regulatory regions. The identification of the DNA sequences bound to the 
nuclear ERp57 has been demonstrated by ChIP and the cloning procedure  of 
the immunoprecipitated fragments in HeLa cells (Chichiarelli et al., 2007). 
The features of these DNA sequences, such as the proximity of MAR region 
and the homology to the non-coding regions of orthologue genes of mouse or 
rat, are compatible with gene expression regulatory function. Futhermore, 
ERp57 was also able to bind regulatory regions of several STAT3-dependent 
genes (Chichiarelli et al., 2010).  
Specific genes with high affinity towards ERp57 were selected, from 
among the ERp57-interacting DNA fragments. In particular, the MSH6 gene 
which encoded for a DNA mismatch repair protein, the TMEM126A gene 
which encoded for a recently discovered mitochondrial transmembrane 
protein and the Ets-1 gene which encoded for a transcription factor and 
potential oncogene were chosen. 
Chromatin digestion by DNase I acts on the nucleosome-free regions of 
the genome, enabling the identification of both ubiquitous and tissue-specific 
regulatory elements. Promoters, enhancers, suppressors, insulators, and locus 
control regions all have been shown to be associated with DNase I 
hypersensitivity sites (Crawford et al. 2004). Mapping of DNase 
hypersensitivity sites has also identified a number of inducible gene 
regulatory elements, such as those associated with genes that are regulated by 
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steroid hormones or cellular differentiation (Gross and Garrard 1988). Our 
data show that MSH6 and TMEM126A sequences associated to ERp57, are 
sensitive to DNase I digestion, supporting the idea of the presence of 
regulatory regions that could turn on the transcribing process. Conversely, no 
sensitive site could be identified within Ets-1 sequences-ERp57 associated, 
suggesting a different function than transcriptional activation for the 
interaction between the examined Ets-1 region and ERp57. 
Previous study has demonstrated the influence of ERp57 in the signaling 
and transcriptional activities of STAT3 by ERp57 RNA interfering (Eufemi 
et al. 2004). Our present experiments show that the silencing of ERp57 
expression impairs MSH6, TMEM126A activation. Ets-1 is up-regulated, and 
this effect does not seem to be statistically significant. 
Iimportant features of ERp57 are represented by its capacity to function as 
amolecular chaperone, hence, to interact with several proteins (Quan et al. 
1995). In addition, ERp57 could form a multiprotein nuclear complex that 
preferentially binds DNA with thioguanine incorporated (Krynetski et al. 
2003). Grillo et al. (2006) have demonstrated that Erp57 is able to associate 
with APE/Ref-1, Ku86 in HepG2, Raji and M14 cell lines. 
The expression of APE/Ref-1 can be up-regulated by a variety of 
Reactive Oxygen Species (ROS) and ROS-generating systems (Kelley and 
Parsons 2001). Interestingly, APE/Ref-1 was recently found to be required 
for the DNA binding activity of STAT3 (Ray et al. 2010). 
ERp57 is known to be over-expressed in a variety of stress conditions 
(Lee 2001) and as shown from the results described above, this protein is also 
associated with MSH6, TMEM126A and Ets-1 gene sequences  
Furthermore, our results obtained from in vitro binding assay with 
biotinylated DNA fragments corresponding to the gene of interest incubated 
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with M14 nuclear extract, have confirmed their association with ERp57 and 
their interaction with APE/Ref-1. Based on these data it is legitimate to 
speculate on the possibility that ERp57 binding MSH6 or TMEM126A or 
Ets-1, recruits APE/Ref-1 for protein complex formation in different cellular 
functions. Moreover, Ku86 and PARP-1 both protein involved in DNA repair 
are not able to bind MSH6, TMEM126A and Ets-1 biotinylated DNA 
fragments. 
In conclusion, in M14 cells a potential MSH6 and TMEM126A 
regulatory sequence has been revealed to be a target of ERp57 and of 
APE/Ref-1. When ERp57 is knocked-down, both MSH6 and TMEM126A 
genes are down-regulated suggesting a regulation by ERp57 at transcriptional 
level.  
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7 Aim of the work II 
 
 
Extensive oxidative stress is a common feature of neurodegenerative 
diseases, such as Amyotrophic Lateral Sclerosis, Alzheimer‟s disease and 
Parkinson‟s disease (PD). Oxidative stress is particularly important at the 
Endoplasmic Reticulum (ER) level, where proteins reach their native 
conformation with the help of a number of enzymes involved in the redox 
control of cysteine residues. If the ER luminal redox system is overwhelmed, 
the loss of the thiol-disulfide redox buffer can impair the oxidative protein 
folding causing luminal accumulation of unfolded/misfolded proteins which 
trigger the Unfolded Protein Respose (UPR). A role for redox imbalance and 
consequent ER dysfunction in neurodegenerative diseases has been suggested 
(Banhegyi et al. 2008), and recently the involvement in neurodegeneration of 
ERp57 has been pointed out (Erickson et al. 2005; Hetz et al. 2005; Kim-Han 
and O'Malley 2007). In particular, it has been demonstrated that in PD 
models, 6-hydroxydopamine (6-OHDA), a widely used parkinsonian 
mimetic, induces an alteration of ERp57 protein which undergoes post-
translational modifications in rats striatum, suggesting an involvement of ER 
stress (Ogawa 2010). In addition, Kim-Han and O‟Malley have demonstrated 
that 6-OHDA leads to the rapid formation of an ERp57-DNA aggresome in 
primary neuronal cells in culture (Kim-Han and O'Malley 2007). 
The aim of the present work was to evaluate the modulation of the 
expression and cellular localization of ERp57 in neuronal cells in culture or 
in vivo in CD1 mice treated with a recently identified parkinsonian mimetic, 
5-S-Cysteinyldopamine (CysDA). 
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We also studied the modulation of the expression, aggregation and 
cellular localization of α-Synuclein, which is a key protein in Parkinsonian 
neurodegeneration. 
In recent years, CysDA has received great attention in view of its possible 
significance as an index of oxidative stress in aging and in neurodegenerative 
processes (Mosca et al. 2006). CysDA is a catecholthioether derivative 
arising from the nucleophilic addition of a thiol to the benzene ring of 
dopamine (DA) following its oxidation to an o-quinone (Zhang and Dryhurst 
1994). DA-quinone addition to Glutathione (GSH), the most abundant thiol 
compound in the cell, gives rise to 5-S-glutathionyldopamine (GSH-DA) 
which is hydrolyzed by peptidases to form free CysDA. 
GSH-DA levels in the brain are very low, and near the limit of 
detection, whereas CysDA levels are easily detectable. This latter compound 
has been identified long ago in autoptic brains of various mammalian species, 
and was found to be highest in humans compared to other mammals, 
particularly in the striatum (Rosengren et al. 1985).  
It is also present in the cerebrospinal fluid of PD patients (Cheng et al. 
1996) and there are circulating antibodies against CysDA in individuals 
affected by PD (Salauze et al. 2005). 
This substance is able to induce apoptotic death via caspases activation, 
mitochondrial membrane depolarization and Complex I inhibition (Spencer et 
al. 2002; Mosca et al. 2006; Mosca et al. 2008).  
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Figure 9.  Proposed pathway of 5-S-cysteinyl-dopamine (CysDA) synthesis in vivo. 
Autooxidation of DA produces the highly reactive DA-quinone, that can undergo 
nucleophilic addition of thiol groups (both free cysteine or glutathione), giving rise mainly to 
the 5-S-isomer (the 2-S-Cys-DA and 2,5-S,S-di-Cys-DA isomers represent less than 20% of 
the total products in vitro). 5-S-glutathionyl-DA can then be converted to Cys-DA by 
peptidases, mainly g-GT. Cys-DA may be further oxidized to dihydrobenzothiazine 
derivatives.(Mosca et al. 2006) 
 
 
Cys-DA has also drawn further attention as a putative precursor of 
neuromelanin, the characteristic pigment occurring in the bodies of 
dopaminergic neurons of Substantia Nigra pars compacta (SNc) and arising 
from the auto-oxidation and polymerization of DA and CysDA (Carstam et 
al. 1991; Zecca et al. 2001). A dramatic reduction of neuromelanin in SN is 
the distinctive anatomopathological feature of PD, which parallels the 
selective degeneration of the dopaminergic neurons of SN, along with the 
accumulation of intraneuronal cytoplasmic inclusions characterized by 
ubiquitinilated alpha-synuclein (α-Syn) aggregates, known as Lewy bodies 
(Venda et al. 2010). 
α-Syn is a presynaptic protein which is natively unfolded, i.e. it can 
assume various conformations depending on the environmental conditions. 
The physiological role of α-Syn is to modulate DA function and metabolism 
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by interacting with key proteins involved in its metabolism and storage 
(Perez and Hastings 2004). A diverse array of evidence is emerging that α-
Syn may undergo aggregation and fibril formation, leading to a loss of 
function, which in dopaminergic neurons may determine a dysregulation of 
the DA pathways with subsequent excess of cytosolic DA, that can enhance 
the neurotoxic effect of α-Syn aggregates (Perez and Hastings 2004). DA 
release into the cytosol can also trigger oxidative stress which might be 
responsible for the dysfunction and death of neuronal cells that contribute to 
pathogenesis and to further protein aggregation. 
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8 Materials and Methods II 
 
8.1 Synthesis of CysDA 
 
CysDA was synthesized as described by Chioccara and Novellino for 
CysDOPA (Chioccara and Novellino 1986). 20 mmol ceric ammonium 
nitrate in 100 ml of 2 M H2SO4 was added to a 10 mmol of DA in 2 M 
H2SO4. The resulting orange reaction mixture was immediately poured at 
once to a vigorously stirred solution of L-cysteine (5 g) in 50 ml of 2M 
H2SO4. The resulting blue solution was directly passed through a column (2 x 
40 cm) of Dowex 50Wx8 (H+ form) equilibrated with water. After washing 
with water, the column was eluted with 0.5 N HCl to eliminate unreacted 
DA. Further elution with 3 N HCl and then 4 N HCl gave a mixture of 
various CysDA isomers (2-S- and 5-S-cysteinyldopamine, and 2,5-S,S-
dicysteinyldopamine). The eluted fractions were combined, reduced to a 
small volume (2 ml) redissolved in water and rechromatographed on a 
Dowex 50Wx2 (2 x 40 cm) equilibrated with 2 N HCl. Elution was carried 
out with 2 N HCl and 10 ml fractions were collected and analyzed 
spectrophotometrically. The second peak eluted (fractions 50-100, with λmax 
254 and 293 nm, relative absorbance 4:3) was collected and after removal of 
the solvent by freeze-drying gave CysDA as a pale brown residue. The purity 
of the product was checked by HPLC, which revealed no contamination by 
other isomers or unreacted dopamine and the identity of the substance was 
further confirmed by Electrospray Ion Mass Spectrometry (molecular mass: 
272,1 Da). The concentration of CysDA in solution was checked 
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spectrophotometrically by using a molar extinction coefficient of 2860 M
-
1
cm
-1
 at 293 nm.  
 
 
8.2 Cell culture and treatment 
 
The human dopaminergic neuroblastoma cell line SH-SY5Y was 
obtained by ICLC (Genova, Italy). The SH-SY5Y cell line has become a 
popular cell model for PD research because this cell line posses many 
characteristics of DAergic neurons. For example, these cells express tyrosine 
hydroxylase and dopamine-β-hydroxylase as well as the dopamine 
transporter (Xie et al. 2010). The cells were maintained in a humidified 
incubator under 5% CO2 at 37°C, and were grown in Dulbecco‟s modified 
Eagle‟s/F12 medium supplemented with 10% heat-inactivated fetal bovine 
serum and 2 mM glutamine. The cells were routinely harvested twice a week 
by trypsinization (0.05% trypsin-EDTA) and plated in 25 cm
2
 culture flasks 
(split 1:4-1:8). Cells at 50-60% confluence were treated with CysDA or 6-
OHDA at a final concentration of 100 μM in culture medium and harvested at 
the indicated times. Cell viability was assessed by trypan blue exclusion. 
 
 
8.3 Animals 
 
Male CD1 mice (25-30 g of weight; Harlan Italy) were used. Upon arrival 
at the laboratory, the animals were housed in an air-conditioned room 
(temperature 21±1 °C, relative humidity 60±10%) with lights on from 8 to 
20h. Males were housed in same-sex groups of 3 individuals in 32 x 14 x 12 
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x cm Plexiglas boxes with a metal top and sawdust as bedding, and with 
pellet food (standard diet purchased from Harlan Italy) and tap water ad 
libitum. Experimental subjects were weighed after the lesion. All the 
experiments were performed in strict compliance with the Italian National 
Laws (DL 116/92), the European Communities Council Directives 
(86/609/EEC). All efforts were made to minimize the number of animals 
used in the study and their suffering. 
 
 
8.4 Surgical procedures 
 
DA-denervating lesions were performed by bilateral injection of 6-
OHDA or CysDA into the dorsal striatum as previously reported (Branchi et 
al. 2008).  
Briefly, on the day of the surgery, mice received an intraperitoneal (i.p.) 
injection of the noradrenaline transporter inhibitor, desipramine (25 mg/kg, 
30 min before surgery) and were anesthetized with equithesin (3 ml/kg, i.p.) 
[Na pentobarbital (0.972 g), chloral hydrate (4.251 g), magnesium sulfate 
(2.125 g), ethanol (12.5 ml), and propylene glycol (42.6 ml) in distilled water 
(total volume, 100 ml)] and positioned on a stereotaxic frame (Kopf 
Instruments, Tujunga, CA). 
6-OHDA and CysDA (2 μg/μl) were separately dissolved in 0.2% 
ascorbate saline. Three different groups of animals were injected with 4 μl of 
6-OHDA solution, CysDA solution, or a corresponding volume of saline 
(SHAM-operated mice) into the dorsal striatum at a flow rate of 0.5 μl/min 
using a 10 μl Hamilton microsyringe with a 30-gauge needle at the following 
coordinates: AP = + 1; ML = ± 1.7; DV = -2.9 mm, tooth bar −2.4 (relative to 
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bregma and midline, in mm). The needle was left in place for 5 min after the 
injection before retraction. Each animal received a total of 16 μg of 6-OHDA 
or CysDA, 8 μg at each side. After surgery, the animals were left undisturbed 
in their home cage  for 21 days and their body-weight was daily monitored. 
A fourth group of intact mice was housed as the 6-OHDA-, CysDA- and 
SHAM-operated rats, but left undisturbed in their home cage. 
 
 
8.5 Monoamine and monoamine metabolites determinations 
 
Mice were sacrificed at 21 days after lesion for the determination of DA, 
noradrenaline (NA), 5-hydroxytryptamine (5-HT) and their metabolites. For 
monoamine and monoamine metabolites assay, the brain was rapidly 
removed and the striata were dissected out on ice, weighed in polypropylene 
vials and homogenated in percloric acid (PCA) 0.1M. Samples were 
centrifuged for 20 min at 15000g (4°C), then the supernatant was used for 
monoamine and monoamine metabolites assays. The endogenous levels of 
DA, DA metabolites (homovanillic acid, HVA and 3, 4-
dihydroxyphenylacetic acid, DOPAC), NA, 5-HT and 5-HT metabolite (5-
hydroxyindolacetic acid, 5-HIAA) were assayed by microbore HPLC using a 
SphereClone 150-mm x 2-mm column (3-µm packing). The detection was 
accomplished with a Unijet cell (BAS) with a 6-mm-diameter glassy carbon 
electrode at +650 mV versus an Ag/AgCl reference electrode, connected to 
an electrochemical amperometric detector (INTRO, Antec Leyden, 
Netherlands). The chromatographic conditions were: (i) a mobile phase 
composed of 85 mM of sodium acetate, 0.34 mM EDTA, 15 mM sodium 
chloride, 0.81 mM of octanesulphonic acid sodium salt, 5% methanol (v/v), 
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pH = 4.85 (ii) a rate flow of 220 μl/min (iii) a total runtime of 65 min. For 
each analysis, a set of standards containing various concentrations of each 
compound (monoamines and their metabolites) was prepared in the acid 
solution. The calibration curves were calculated by a linear regression. The 
retention times of standards were used to identify peaks and peak area were 
used to quantify monoamine levels. Results were normalized to the weight of 
the wet tissue. 
 
 
8.6 Detection of protein carbonylation by OxyBlot 
 
The carbonyl assay is widely used to study oxidative protein damage 
in tissues and in cells. The reactive oxygen species (ROS) attack on 
aminoacid residues (namely His Arg Lys and Pro) generates carbonyls that 
can be detected after reaction with 2,4-dinitrophenylhydrazine. Brain 
specimens or treated cells were homogenized in 0.25 M sucrose, 100 μM 
TRIS-HCl buffer (pH 7.4) containing 100μM MgCl2, 80 μM EDTA, and 
protease inhibitors, sonicated for 5 sec and centrifuged at 400g to remove 
debris, whereas cells were treated as above described to isolate nuclear and 
cytosolic proteins. Protein oxidation was measured by OxyBlot Protein 
Oxidation Detection Kit (Millipore), following manufacturer instructions. 
Briefly, samples (5 μl) were derivatized at room temperature for 20 min in 10 
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mM 2,4-dinitrophenylhydrazine (DNPH) and 5 μl of 12% sodium dodecyl 
sulfate (SDS). Samples were neutralized with 7.5 μl of neutralization solution 
(2 M Tris in 30% glycerol). Derivatized samples (250 ng) were then blotted 
onto a nitrocellulose membrane under vacuum using a slot-blot apparatus 
(Bio-Rad). Membranes were blocked with 3% BSA in Tris Buffer saline 
containing 0.1% Tween (TBS-T) for 1h and next incubated with rabbit 
antibody to protein-bound DNP (diluted 1:150) for 90 min. After washing 
with TBS-T, membranes were incubated with anti-rabbit IgG alkaline 
phosphatase secondary antibody (1:5000) in TBS-T for 1 h at room 
temperature. The membrane was washed in TBS-T and developed using a 
solution of nitrotetrazolium blue chloride (0.2 mM) and 5-bromo-4-chloro-3-
indolyl phosphate dipotassium (0.4 mM) in alkaline phosphate buffer (0.1 M 
Tris, 0.1 M NaCl, 5 mM MgCl2; pH 9.5). Dried blots were quantified using 
QuantityOne image analysis (BioRad). 
 
 
8.7 Determination of GSH/GSSG 
 
Glutathione (GSH) is one of the most important cellular antioxidants. 
It acts as a thiol buffer in the cells and is important in the detoxification of 
potentially harmful endogenous compounds and xenobiotics. GSH can be 
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readily oxidized to its disulfide (GSSG) and the ratio of both forms is crucial 
for the characterization of the oxidative stress in cells. 
GSH and GSSG were determined by HPLC after their derivatization 
with OPA to form a stable, highly fluorescent tricyclic derivate (Hissin and 
Hilf 1976). Tissue specimens and treated cells were resuspended in cold 10% 
metaphosphoric acid. After incubation at 4°C for 15 min, the mixtures were 
centrifuged (20000g, 15 min, 4°C) and supernatants stored at −80°C until 
analysis by HPLC. To determine GSH, 50 μl of the supernatant were treated 
with 1.0 ml of 0.1% EDTA in 0.1M phosphate buffer, pH 8.0. 20 μl of this 
mixture were treated with 300 μl of 0.1% EDTA in 0.1M phosphate buffer, 
pH 8.0, as a diluent, and 20 μl of 0.1% OPA in methanol. After incubation at 
25°C for 15 min in the dark, the mixture was filtered and analyzed by HPLC. 
To determine GSSG, 200 μl of the supernatant were incubated at 25°C with 
200 μL of 40 mM N-ethylmaleimide (NEM) for 25 min in the dark, then 750 
μl of 0.1 M NaOH were added. 20 μl of this mixture were used for HPLC 
analysis, using the procedure above described for GSH, except that 0.1 M 
NaOH was employed as diluent. 
The HPLC system consisted of a Waters apparatus, equipped with a 
600 pump and pump controller, a Waters 717 plus autosampler, an X-Bridge 
column (C18 reverse phase, 4.6x250mm, 5μm particle size - thermostated at 
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37°C with a 10mm guard column of the same material matrix) and a 
Shimadzu RF-551 spectrofluorometric detector. 
The mobile phase consisted of 15% methanol in 25 mM phosphate 
buffer, pH 6.0. The flow rate was kept constant at 0.5 ml/min. The 
excitation/emission wavelengths were set at 350/420 nm. 
Peak identification and quantitation was performed by automatic peak 
area integration using a dedicated software (Millennium32, Waters). 
 
 
8.8 Western Blot analysis 
 
Nuclear and cytosolic proteins were obtained from treated SH-SY5Y 
cells by  ProteoJET™ Membrane Protein Extraction Kit (Fermentas, M-
Medical srl, Milan, Italy). To verify the correct separation of the two 
fractions, a Western Blot was performed by using specific antibodies againt 
Lamin A and C (Millipore, Vimodrone, Milan, Italy) and Vinculin (Santa 
Cruz Biotechnology, Inc., DBA Italia, Segrate, Milan, Italy), specific for the 
nuclear and cytosolic fractions, respectively. 
Brain tissues were treated with ice-cold lysis buffer (0.10 mM Tris pH 
8, 0.25 M sucrose, 0.10 mM MgCl2, 0.80 mM EDTA) containing 1 mM 
PMSF and 1% protease inhibitor cocktail (Roche) and immediately 
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homogenized with 15 pestel strokes using a Dounce glass homogenizer. The 
homogenate was sonicated for 5 sec on a LABSONIC M sonicator (B.Braun 
Biotech International) at an amplitude of 60, and centrifuged at 12000g for 5 
min to remove debris. 
Tissue lysates and cell extracts were separated by electrophoresis on 
SDS-PAGE on 12% Mini-PROTEAN
®
 TGX™ Precast Gel (Biorad 
Laboratories) followed by transfer to a Protran® Nitrocellulose Membrane 
(Whatman GmbH, Dassel, Germany). The membrane was blocked with 5% 
non fat dry milk in PBS-T buffer for 1 h at room temperature prior to 
incubation overnight at 4°C with two different primary antibodies, i.e. anti-α-
Syn (Cell Signaling, 1:500) or anti-ERp57 (1:300, polyclonal antibody 
obtained by immunizing rabbits with ERp57 purified from pig liver 
(Chichiarelli et al. 2007)). 
The proteins were visualized by ECL detection kit (GE Healthcare). 
 
 
8.9 Real time RT-PCR determination of ERp57 and α-Syn  
 
To analyze the expression of ERp57 and α-Syn mRNA, total RNA 
was extracted from adherent cells using TRIZOL
®
 reagent (Invitrogen 
Corporation, Carlsbad, CA, USA) in accordance with the manufacturer‟s 
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instructions. Briefly, 10
7
 cells were washed with ice-cold PBS and lysed in 
1ml of TRIZOL reagent. The RNA pellet was resuspended in diethyl 
pyrocarbonate (DEPC) treated water and stored at -80°C until use. An aliquot 
of each RNA was loaded onto 1% agarose gel to visualize and quantify the 
degree of RNA integrity. cDNA was synthesized from 1,5 μg of total RNA 
using as reverse trascriptase QuantiTect
®
 Reverse Transcription Kit (Qiagen) 
in accordance with the manufacturer‟s instructions, and analyzed by real-time 
polymerase chain reaction (qPCR). cDNA concentration was determined 
using a GeneQuant II RNA/DNA Calculator (Pharmacia Biotech). 
The Two-step SYBR-Green I-based real time RT-PCR was carried 
out using an MJ MiniOpticon™ Detection Systems (Bio-Rad Laboratories, 
Milan, Italy). Amplification was carried out with 500 ng of cDNA, using 
Maxima
®
SYBR green qPCR Master mix (2x) (Fermentas, Milan, Italy) in a 
final volume of 25 μl. Each sample was analyzed in triplicate. PCR 
conditions were 95°C for 10 minutes followed by 40 cycles of 95°C for 15 
seconds and 60°C for 1 minute. 
To amplify mRNA the following primers were used:  
-ERp57 primers were purchased from Qiagene (ERp57 or PDIA3, Ref.Seq 
Accession: NM_005313.4). 
-α-Syn primer was designed by MWG-Biotech AG using Primer Express 
software (Applied Biosystems) and were synthesized by Primm 
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(Milan, Italy): 
forward primer: 5' CGA AGT CTT CCA TCA GCA GTG 3‟ 
reverse primer: 5' AAG GGA AGC ACC GAA ATG 3' 
The results were analyzed using the Gene Expression Macro™, Version 1.1 
(Bio-Rad), which recorded the threshold cycle (Ct).  
Untreated cell sample (CTL) was used as control and target gene Ct values 
were normalized against RPS27A (RPS27A_2_SG, Ref.Seq Accession: 
NM_002954, obtained from Qiagen). Data were analyzed using the 2
-ΔΔCt
 
method and expressed as fold change compared with CTL (Relative 
Quantity). 
 
 
8.10 Protein determination 
 
Protein content of cellular and tissue homogenates was evaluated by 
the BioRad reagent (Bio-Rad Laboratories, Segrate, Milan, Italy) using 
bovine serum albumin as a standard. 
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8.11 Statistical analyses 
 
Experiments were repeated at least three times and all the results are 
expressed as the mean value ± Standard Deviation (SD). Statistical 
comparison between groups was made using Student‟s t test or post hoc 
anova (Tukey‟s). p values<0.05 were regarded as significant. 
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9 Results II 
 
9.1 CysDA induces selective DA depletion in the striatum 
 
Among PD animal models, one of the most commonly used is the 
induction of neuronal lesion by the intrastriatal injection of 6-OHDA in rats 
or mice. This latter substance is one of the known parkinsonian mimetics and 
is widely used to study mechanisms of cell death of dopaminergic neurons in 
PD, providing permanent dopaminergic depletion selective to the 
nigrostriatal pathway by stereotaxic surgical administration (Blandini et al. 
2008).  
CysDA was found to be highly neurotoxic in vitro, both on primary 
neural cells and on immortalized neuroblastoma dopaminergic cells (Spencer 
et al. 2002; Mosca et al. 2006). In this study we aimed at verifying whether 
the intrastriatal injection of CysDA caused the same degenerative effects 
exerted by 6-OHDA. To this purpose, the effect of this substance on 
catecholaminergic neurotransmitter levels, the rate limiting enzyme in 
neurotransmitter synthesis, were evaluated in brains of mice subjected to DA-
denervating lesions by bilateral injection of either CysDA or 6-OHDA.  
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Following both CysDA and 6-OHDA injections, DA concentration in 
the striatum was significantly reduced (Fig. 10A). 
 
A)
 
 
B)
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C)
 
 
 
Figure 10.  Neurotransmitter levels in the brains of mice treated with CysDA or  
6-OHDA. Following both CysDA and 6-OHDA injections in the striatum, as 
described in Material and Methods, the neurotransmitter levels were determined by HPLC 
analysis. A) Dopamine (DA) and its metabolite homovanilic acid (HVA) as a sign of 
neurological damage; B) noradrenaline (NA) and its metabolite 3-methoxy-4-
hydroxyphenylethyleneglycol (MOPEG); and C) serotonin (5-HT) an its metabolite 5-
hydroxyindoleacetic acid (5-HIAA). Values are expressed as pg of neurotransmitter/mg of 
wet tissue. Data represent the mean of at least three independent experiments ± S.D. *p<0.05 
vs SHAM-operated mice; **p<0.01 vs SHAM-operated mice; ***p<0.001 vs SHAM-
operated mice. 
 
 
 
In particular, post hoc Tukey‟s test indicated that CysDA treatment 
induced a 35% reduction in DA concentration compared to SHAM-operated 
mice (p<0.05), whereas the lesion induced by 6-OHDA was more 
pronounced, leading to a 65% reduction in DA (p<0.001). The DA turnover 
(calculated as the HVA/DA ratio) was not affected by both neurotoxins 
(Fig.10A). Moreover, no significant effect on noradrenergic and serotonergic 
neurotransmission was evidenced in the striatum of mice injected with 
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CysDA or 6-OHDA (Fig. 10B and C). Likewise, NA turnover (calculated as 
the MOPEG/NA ratio) and 5-HT turnover (calculated as the 5-HIAA/5-HT 
ratio) were not affected. 
 
 
9.2 CysDA treatment of both SH-SY5Y cells and mice brains 
induces extensive oxidative stress 
 
It is ascertained that the toxic properties of CysDA and of 6-OHDA 
are mediated by their ability to induce oxidative stress, which has a 
prominent role in the neurodegenerative process of PD (Mosca et al. 2006; 
Miller et al. 2009; Reiter et al. 2010). Evidences suggest that dopaminergic 
neurons may be particularly vulnerable to oxidative injury, thus ROS 
generation due to the catecholamine metabolism could account, at least in 
part, for the selective degeneration of these neurons (Fahn and Cohen 1992; 
Dauer and Przedborski 2003). In particular, several reports indicate that the 
GSH-GSSG equilibrium is seriously compromised in parkinsonian brains 
(Sian et al. 1994) and that protein carbonylation increases with age and in 
neurodegenerative diseases (Alam et al. 1997; Sultana et al. 2009). 
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- GSH/GSSG detection 
 
Glutathione plays important roles in biological systems, primarily in 
the detoxification of potentially harmful xenobiotics and in the antioxidant 
defence response. It can be readily oxidized to its disulfide and the ratio of 
both forms is crucial for the characterization of the oxidative stress in cells. 
Indeed oxidative stress in neurodegeneration has a profound effect on the 
cellular thiol balance and can lead to a decreased GSH/GSSG ratio and to a 
decrease of the total amount of GSH (Sofic et al. 1992; Sian et al. 1994). 
GSH and GSSG amounts were determined in different brain regions 
of mice treated with CysDA or 6-OHDA. The analysis revealed that the 
levels of GSH and GSSG were comparable in striatum, hippocampus and 
prefrontal cortex of SHAM-operated mice (Fig. 11A). In these animals GSH 
amount was found to be about 1 μmol per gram of tissue, whereas GSSG was 
about 0.25 μmol per gram of tissue. Compared to SHAM-operated mice, 
CysDA- and 6-OHDA-treated mice showed significantly reduced levels of 
GSH in all brain areas. Conversely, the amount of GSSG does not seem to be 
affected by both neurotoxins treatment in any brain area. 
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A)
 
B) 
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Figure 11.  GSH levels in brains and in cells after CysDA and 6-OHDA treatment. GSH 
and GSSG were determined by HPLC with fluorometric detection after derivatization with 
OPA as described in Materials and Methods. A) GSH and GSSG levels in different brain 
areas of SHAM-operated mice or mice treated with CysDA or 6-OHDA. Data are expressed 
as μmol/g of tissue (fresh weight). Data represent the mean of n=6 different brain specimens 
± S.D. *p<0.05 and **p<0.01 versus SHAM-operated mice. 
B) GSH amount (% versus control) in cells treated with 100 μM CysDA or 6-OHDA at 
various times. C) GSSG increase (fold to control) in cells treated with 100 μM CysDA or 6-
OHDA at various times. Data represent the mean of at least three independent experiments ± 
S.D. *p<0.05 and **p<0.01 versus control cells (CTRL). 
 
 
The kinetics of GSH oxidation was evaluated in SH-SY5Y cells 
exposed to CysDA or 6-OHDA at various times. The data revealed that GSH 
rapidly reacted to oxidative stress induced by both neurotoxins. Evaluation of 
the net amount of GSH in CysDA or 6-OHDA treated cells, indicated a rapid 
depletion of GSH by about 40 or 55%, respectively, within 3 hours, which 
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was persistent up to 24 hours (Fig. 11B). Within 1 hour of treatment, the 
amount of GSSG was more than six times higher in 6-OHDA-treated cells 
and 3 times higher in CysDA-treated cells compared to controls, reaching a 
seven-fold increase and four-fold increase, respectively, after 3 hours of 
treatment (Fig. 11C). The amount of GSSG returned to basal level in 
prolonged incubations, up to 24 hours. 
 
- Protein carbonylation 
 
Oxidative stress may also induce protein damage, which can be 
evaluated by assessing the level of protein carbonylation in brain. Reactive 
oxygen species (ROS) are able to react with amino acid residues thus 
producing carbonyl groups which can be measured spectrophotometrically 
after reaction with 2,4-dinitrophenylhydrazine. To evaluate whether CysDA 
and 6-OHDA treatment in mice induced protein carbonylation, different brain 
regions were isolated and analyzed. A significant increase in protein 
carbonylation was detected in the striatum which is the prime target of the 
neurotoxins (Fig. 12A). 
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A) 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
Figure 12.  Protein carbonylation levels in brains and in cells after CysDA and 6-OHDA 
treatment. Proteins obtained from A) different regions of mice brains or from B) SH-SY5Y 
cells treated with 100 μM CysDA or 6-OHDA at various times, were analyzed by OxyBlot as 
described in Materials and Methods. Briefly, cells lysates or brain homogenates were 
derivatized with DNPH, blotted onto nitrocellulose membranes and probed with anti-DNP 
protein adducts polyclonal antibody. Data represent the mean of at least three independent 
experiments or n=6 brains specimens ± S.D. *p<0.05 respect to SHAM-operated mice or 
control cells (CTRL). 
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In this brain region, both CysDA and 6-OHDA induced a significant 
increase in protein carbonyls by about 20% compared to controls, whereas in 
the hippocampus a 10% increase in carbonyls can be observed. At the 
prefrontal cortex level, protein carbonylation seems not to be affected by both 
neurotoxins.  
The time course of protein carbonylation was studied in the cellular 
model of PD, in which SH-SY5Y cells were treated either with CysDA or 
with 6-OHDA. When cells were exposed to the neurotoxins, a relevant 
increase in protein carbonylation was observed, reaching a maximum after 6h 
of incubation at 24 h (Fig. 12B). 
 
 
9.3 CysDA modulates ERp57 levels and -Syn aggregation  
 
It is well known that oxidative stress induces a cellular response which 
involves the endoplasmic reticulum and a number of proteins whose 
expression and aggregation are influenced by the redox status of the cell. In 
particular we have analyzed protein levels in various brain regions and 
cellular fractions by Western blot, focusing our attention on ERp57, the stress 
protein which has been recently linked to neurodegeneration and on -Syn, a 
key protein in Parkinson disease. 
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As regards Erp57, the level of this protein was found to be increased 
in the striatum, whereas in the hippocampus and at the cortex level no effect 
can be evidenced (Fig. 13A and B).  
A) 
 
 
 
B) 
 
 
 
 
 
 
 
 
 
Figure 13.  Western blot with ERp57 antibodies in mice brains. 
A) Representative Western blot obtained from different brain regions. Proteins (≈70 μg) 
were loaded onto 12% SDS-PAGE gel, blotted onto nitrocellulose membrane and incubated 
with specific antibodies against ERp57. The bands were revealed by ECL 
chemiluminescence kit. B) Densitometric analyses of bands corresponding to ERp57 protein 
after CysDA or 6-OHDA treatment were performed with ImageJ software, and normalized to 
β-actin. Data are reported as percentage of control values, i.e. SHAM-operated mice, and are 
the mean ± S.D. of at least three brain specimens. 
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.ERp57 level in cells treated with both neurotoxins, was increased up 
to 24 hours at the cytosolic level on the contrary ERp57 was transiently 
increased within 3 hours in the nuclei (Fig. 14A and B ). 
 
A) 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
Figure 14.  Western blot with ERp57 antibodies in SH-SY5Y cells. 
A) Representative Western blot of ERp57 protein of cytosol and nuclei obtained from SH-
SY5Y cells treated with 100 μM CysDA or 6-OHDA at various times. Proteins (≈70 μg) 
were loaded onto 12% SDS-PAGE gel, blotted onto nitrocellulose membrane and incubated 
with specific antibodies against ERp57. The bands were revealed by ECL 
chemiluminescence kit. Cytosolic and nuclear fractionation was verified by using Vinculin 
and Lamin A and C specific antibodies. B) Densitometric values of cytosol and nuclei were 
quantified by using ImageJ software and normalized to Vinculin and Lamin A and C. Each 
value represents the mean ± SD of at least three independent experiments and is given as 
percentage of control cells (CTRL).  
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Western blot analysis allowed to detect both the monomeric -Syn 
form, which has an apparent molecular weight (MW) of 18kDa, and the 
dimeric form at 36 kDa. The presence of oligomeric forms could also be 
evidenced, with MWs higher than 54 kDa. For quantification purposes, only 
the momeric and dimeric forms were analyzed, due to the extreme variability 
and heterogeneity of the oligomeric forms. After mice treatment with CysDA 
and 6-OHDA, a two-fold increase in dimeric α-Syn form was observed 
specifically at the prefrontal cortex level with respect to SHAM-operated 
mice. On the contrary, the monomeric form seemed not to be affected in any 
cerebral area (see Fig.15 A and B). 
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A) 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
 
 
Figure 15.  Western blot with α-Syn antibodies in mice brains.  
A) Representative Western blot obtained from different mice brain regions treated with 
CysDA or 6-OHDA. Proteins (≈70 μg) were loaded onto 12% SDS-PAGE gel, blotted onto 
nitrocellulose membrane and incubated with specific antibodies against α-Syn. The bands 
were revealed by ECL chemiluminescence method. B) Densitometric analyses of bands 
corresponding to the monomeric (≈18kDa) and to the dimeric (≈36kDa) forms of α-Syn after 
CysDA or 6-OHDA treatment were performed with ImageJ software, and normalized to β-
actin. Data are reported as percentage of control values, i.e. SHAM-operated mice, and are 
the mean ± S.D. of at least three brain specimens.  
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To assess α-Syn level and cellular localization, cytoplasm and nuclei 
fractions were obtained from SH-SY5Y cells treated with CysDA and 6-
OHDA at various times. In the cytosol, both neurotoxins treatment induced a 
time-dependent increase in dimeric α-Syn level, whereas the monomeric form 
was increased within 1h and decreased in prolonged incubations, being 
absent at 24 hours (Fig. 16A and B). In the nuclei, only the monomeric form 
was present and was decreased compared to control within 8 hours of 
treatment, while at 24 hours it was found to be absent like in the cytosolic 
compartment (Fig. 16A and B). 
A) 
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Figure 16.  Western blot with α-Syn antibodies in SH-SY5Y cells. A) Representative 
Western blot obtained from cytosol and nuclei fractions of SH-SY5Y cells treated with 100 
μM CysDA or 6-OHDA for 3 hours. Proteins (≈70 μg) were loaded onto 12% SDS-PAGE 
gel, blotted onto nitrocellulose membrane and incubated with specific antibodies against α-
Syn. The bands were revealed by ECL chemiluminescence method. Cytosolic and nuclear 
fractionation was verified by using Vinculin and Lamin A and C specific antibodies. B) 
Densitometric values of α-Syn bands present in the cytosol or nuclei after CysDA or 6-
OHDA treatment. Optical density was quantified by using ImageJ software, and normalized 
to Vinculin or Lamin A and C, respectively. Each value represents the mean ± SD of at least 
three independent experiments and is given as percentage of control cells (CTRL).  
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9.4 CysDA induces an increase of ERp57 and -Syn gene 
expression  
 
Because several neurotoxin such as MPP
+
 and isoquinoline 
derivatives induced α-Syn increase, the expression level of ERp57 and of -
Syn mRNA from SH-SY5Y cells exposed to CysDA or to 6-OHDA were 
evaluated. 
The real time amplification of the specific primers relatives to ERp57 
and -Syn genes was compared to RPS27A gene, used as endogenous 
control. ERp57 expression was increased within 3 hours and returned to basal 
level within the 24 hours of incubation (Fig. 17A). 6-OHDA treatment gives 
rise to the same expression trend for the two genes, but with a lower mRNA 
level compared to CysDA treatment.  
The quantification of the relative transcript levels, from three 
independent experiments, demonstrated that after CysDA treatment, -Syn 
expression was significantly upregulated within 6 hours up to four-fold 
compared to controls (Fig. 17B) 
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Figure 17.  qRT-PCR of ERp57 and α-Syn. 
mRNA was extracted from SH-SY5Y cell treated or untreated with CysDA and 6-OHDA, as 
described in Material and Methods. RPS27A (QuantiTect
®
 QIAGEN) gene was used as 
reference for normalization and fold inductions were calculated using the formula 2
−(ΔΔCt)
. 
The relative quantification was analyzed using Gene Expression analysis for iCycler iQ real-
time PCR detection system software, Version 1.10 (Bio-Rad Laboratories, Ltd.). The values 
represent the mean ± SD of at least three independent experiments. * p < 0.05 versus control 
cells (CTRL)..  
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10 Discussion II 
 
Although the pathological phenotype and clinical symptoms of PD are 
well described, its aetiology and the mechanism(s) responsible for the 
neurodegeneration are still poorly understood. Genetic forms of the disease 
account for only 5-10% of cases of PD, while the rest are sporadic forms of 
unknown origin, hence a combination of environmental factors and genetic 
susceptibility has been proposed to justify the onset of the disease in most 
cases (Olanow and Tatton 1999).  
The finding that the meperidine analog MPP
+
 is able to induce 
selective neurodegeneration of catecholaminergic neurons in humans thus 
causing clinical manifestations typical of PD, has prompted research for 
endogenous substances which may be responsible for selective dopaminergic 
neurodegeneration in PD. Recent evidence point to CysDA as an endogenous 
neurotoxin. CysDA is a catecholthioether which, along with DA, is the 
building block of neuromelanin, the characteristic pigment of SN. 
Neuromelanin synthesis is an important protective process because the 
melanic pigment is thought to be responsible of the removal of reactive/toxic 
species that would otherwise cause neurotoxicity (Zucca et al. 2004). 
However, if the neuromelanin pathway is impaired, deleterious DA-quinone 
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species accumulation such as o-semiquinones can sequester GSH and then 
generate excess catecholthioethers and in turn benzothiazines. These 
compounds are potent inhibitors of mitochondrial pyruvate dehydrogenase 
(i.e., complex I/Krebs cycle) and complex I of the respiratory chain, and can 
promote α-synuclein fibrillization (Mazzio et al. 2011).  
Neurotoxins which are known to be responsible for neurodegeneration 
in PD (i.e. 6-OHDA, MPP
+
, paraquat, rotenone) have some common features: 
they are able to induce oxidative stress, to inhibit complex I of the respiratory 
chain and to be selectively toxic to dopaminergic cells. Most of these 
characteristics have been proven to be also typical of CysDA (Spencer et al. 
2002; Mosca et al. 2006; Mosca et al. 2008). Furthermore, CysDA was 
demonstrated to disrupt DA trafficking in vivo and in vitro, thus interfering 
with DA uptake and possibly contributing to striatal neurodegeneration in PD 
(Sidell et al. 2001). 
The first aim of the present study was to demonstrate whether CysDA 
could exert neurotoxicity in vivo. The data obtained demonstrate that 
intrastriatal injection of CysDA in CD1 mice caused a depletion of DA, 
without affecting serotonergic or noradrenergic systems. CysDA effect was 
similar to that observed for 6-OHDA, though the DA deficit was less 
pronounced. This effect may reflect an intrinsic difference between the two 
drugs, i.e. 6-OHDA probably leads to a more rapid and thus less chronically 
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progressive lesion of the nigro-striatal pathway compared to CysDA. The less 
pronounced toxicity of CysDA that we observed could actually represent an 
advantage in animal models of PD, given the chronic and long-lasting nature 
of the disease. This data suggest that CysDA may exert its selective 
neurotoxic effect by entering the cells through the dopamine transporter as 
already demonstrated for MPP
+
 (Storch et al. 2004). 
 
 
10.1 CysDA can induce oxidative stress both in vivo and in vitro 
 
Previous work has demonstrated that CysDA is able to induce an 
increase in Reactive Oxygen Species in neuronal cells in culture, along with 
caspases activation and induction of mitochondrial dysfunction (Spencer et 
al. 2002; Mosca et al. 2008). Data regarding the prooxidant effect of CysDA 
in vivo are lacking, hence we aimed at verifying whether CysDA may alter 
the level of the typical oxidative stress markers, such as protein carbonyls 
and GSH levels in mice brains and in cells. 
Different authors detected protein carbonylation in the striatum of PD 
affected patients and in other brain regions such as the cerebellum and the 
prefrontal cortex (Alam et al. 1997; Ferrer 2009). Our results on protein 
carbonylation in mice brains indicate that there was an increase in oxidized 
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proteins in the striatum after treatment with both neurotoxin whereas at the 
hippocampal level the effect was less evident. The increase in carbonylation 
is statistically significant only for CysDA, however, 6-OHDA exerted a 
similar effect, and failed to reach statistical significance due to high standard 
deviation. Conversely to that observed in PD affected patients, in our model 
no protein carbonyls were detected in the prefrontal cortex. This difference 
may be justified by the selective lesion induced in the experimental model 
and by the timing of damage onset. Indeed, as already pointed out, 
neurodegeneration in PD is a slow process in which the impairment of 
neuronal function is the result of a progressive and continuous accumulation 
of damaged/disfunctioning molecules, contrary to what happens in the animal 
models, in which neuronal death is an acute event due to the fact that the 
neurotoxin is delivered in high amounts in a single shot at the striatal level.  
Another characteristic feature of PD brains, directly related to 
oxidative stress, is the reduced GSH/GSSG ratio and the pronounced 
decrease of total GSH in brain specimens (Sofic et al. 1992). Here, we 
demonstrate that CysDA treatment induces GSH oxidation and depletion, and 
that this phenomenon is similar to that observed in PD affected patients 
where GSH oxidation does not seem to be accompanied by a corresponding 
increase of GSSG, which is formed in minor amount. Our data are also in 
good agreement with previous findings indicating an involvement of the GSH 
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cycle in the melanin-induced apoptotic death in SH-SY5Y cells, in which DA 
and synthetic pheomelanin showed a low concentration of GSH with respect 
to control (Naoi et al. 2008). It is notable that decreased a GSH level in the 
substantia nigra represents an early event in the pathological process that 
underlies PD (Martin and Teismann 2009). The question as to whether GSH 
depletion is due to oxidative stress or to alteration of its metabolic pathway 
still remains open. Some authors evidenced an alteration in the activity of key 
enzymes of the metabolism of GSH in PD brains, that was not confirmed in 
later work (Sian et al. 1994). However, there is an undoubted participation of 
the GSH/GSSG system in the response to the stress exerted by CysDA and in 
PD.  
 
 
10.2 α-Synuclein expression and aggregation are prompted by 
CysDA treatment 
 
Recent studies link oxidative stress to protein misfolding and to the 
Unfolded Protein Response (UPR) (Rao and Bredesen 2004; Holtz et al. 
2006). Our data indicate that CysDA is able to perturb redox omeostasis of 
the cell thus possibly triggering protein misfolding, as evidenced by the 
increase in α-Syn aggregation. In vivo experiments demonstrated an increase 
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in α-Syn aggregated forms in the prefrontal cortex with both neurotoxins. 
These data are in agreement with previous findings which indicate that there 
is an involvement of the prefrontal cortex in Parkinson‟s disease (Ferrer 
2009). In particular, an increase of the α-Syn dimeric form was evidenced in 
the prefrontal cortex with respect to the striatum. The dimeric form of the 
protein can be considered as a marker of oxidative stress and its formation is 
an essential step in α-Syn aggregation as demonstrated by Krishnan and 
colleagues (Krishnan et al. 2003). Indeed, the critical rate-limiting step in 
nucleation of α-Syn fibrils under physiological conditions is the oxidative 
formation and accumulation of the dimeric form linked via a dityrosine 
residue. This dimer is able to form a prenucleus that stimulates the 
aggregation of the protein. The evidence that oxidation is an essential step in 
α-Syn aggregation is supported by many findings indicating that different 
methionine oxidation, nitration and MDA-Lysine of α-Syn, are involved in 
the folding and aggregation in the different brain regions (Ferrer,2009).  
Treatment of SH-SY5Y cells with both neurotoxins evidenced an 
increase of α-Syn protein level within 6 hours, that is consistent with the high 
mRNA level determined by qRT-PCR analysis. In the cytosol, both the 
dimeric and the monomeric forms of the protein were present, whereas in the 
nuclei only the monomeric form was detected, along with small amounts of 
oligomers. Previous work has demonstrated that α-Syn can form a stable 
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complex with histone H1, due to the significant presence of basic aminoacid 
residues in histone H1, which can electrostatically interact with the acidic C-
terminal domain of α-Syn enriched in acidic residues (Goers et al. 2003). 
This interaction can dramatically accelerate fibrillation of the protein, giving 
rise to high molecular weight protofibrils and fibrils which cannot be 
detected and quantified by Western blot due to their extremely high 
molecular weight. The pathophysiological implications of this interaction are 
still not clarified, however, Goers and colleagues hypothesized that α-Syn-
histone H1 complexes could have a regulatory role by decreasing the pool of 
free histones available for DNA binding, thus affecting transcriptional 
machinery (Goers et al. 2003). 
 
 
10.3 Oxidative stress and the unfolded protein response 
 
GSH is the major redox buffer of the ER lumen. An alteration of the 
thiol-disulfide redox buffer can impair the oxidative protein folding, causing 
the luminal accumulation of unfolded/misfolded proteins, which triggers the 
Unfolded Protein Response (UPR) and causes ER stress. Accumulating 
evidence suggests that ER stress induced by aberrant protein degradation is 
implicated in PD (Quan et al. 1995). The presence of ERp57 , one of the 
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proteins involved in ER stress, was  evidenced in the brain of PD affected 
subjects (Wilhelmus et al. 2010). These authors demonstrated that ERp57 has 
a different staining pattern between PD subjects and aged-matched controls 
in melanized neurons of SN, i.e. a homogeneous cytoplasmic 
immunoreactivity in controls,  and a granular distribution pattern in PD 
specimens. Notably, 6-OHDA was demonstrated to induce ERp57 
upregulation in cultured neuronal cells including dopaminergic neurons, and 
was found to induce ROS-mediated UPR, which seems to initiate apoptosis 
via mitochondrial involvement (O'Malley et al. 2003; Holtz et al. 2006). 
Based on these results it has been hypothesized that ERp57 may play a role in 
6-OHDA-mediated UPR induction. 
Our results indicate that in mice treated with both CysDA and 6-
OHDA there is an increase of ERp57 protein level in the striatum, the brain 
region directly involved in the lesion. Conversely, in the other brain areas, 
the level of this protein does not seem to be affected. Our data are in 
agreement with previous report which demonstrated that, after intracisternal 
administration of 6-OHDA in rats, there was an increase of ERp57 protein 
level in the striatum and midbrain 12h after treatment up to two weeks, 
indicating the induction of this protein (Akazawa et al. 2010). Treatment of 
SH-SY5Y cells with both neurotoxins evidenced an increase of ERp57 
protein level within 3 hour, that is consistent with the high mRNA level 
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determined by qRT-PCR analysis, further supporting in vivo data. 
The increased ERp57 level is a cellular response to oxidative stress 
exerted by the neurotoxins that induce perturbation of GSH/GSSG ratio. It 
can be speculated that in these conditions ERp57 may act as a chaperone to 
prevent protein misfolding and aggregation of α-Syn, as already hypothesized 
for Amyloid-beta peptide (Erickson et al. 2005). 
In conclusion, our results demonstrate that CysDA exerts neurotoxic 
effects similar to 6-OHDA, supporting the hypothesis that CysDA may be an 
endogenous parkinsonian mimetic, able to induce α-Syn overexpression and 
aggregation, ER stress and consequent neurodegeneration. 
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